It has been acknowledged, that the National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), parts of the National Institutes of Health (NIH), have teamed with Group Health Cooperative in Seattle and Henry Ford Health System in Detroit for the initiation of a study to investigate the interest level of healthy, young adults in receiving genetic testing for eight common conditions. It is called the Multiplex Initiative and is reported to concentrate to look at how people willing to participate in the tests will interpret and utilize the results for framing precise health care decisions in the future.

It has been stated, that the test being used is designed to yield information about 15 different genes performing a considerable role in type 2 diabetes, coronary heart disease, high blood cholesterol, high blood pressure, osteoporosis, lung cancer, colorectal cancer, and malignant melanoma.

The U.S. Food and Drug Administration (FDA) is reported to warn pharmaceutical manufacturers, suppliers, drug repackers, and health professionals that amalgam medications to be watchful at best towards assuring that glycerin, a sweetener commonly used in the international sector in liquid over-the-counter and prescription drug products, does not get unhygienic with diethylene glycol (DEG), a known poison used in antifreeze and as a solvent. It has been confirmed, that today, the agency is staging its typed list of guidance to industry advocating methods of testing glycerin and other controls for the recognition of any infectivity with DEG before its use in the manufacturing or preparation of pharmaceutical products.

The FDA is accountable to the protection of the public health through the assurance of the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, including the nation’s food supply, cosmetics, and products emitting radiation. The organization also operates for the advancement of the public health through helping to speed innovations of making medicines and foods more effective, safer, and more affordable.

It has come to the knowledge that an advanced imaging technique known as electron tomography has allowed researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to envisage an “entry claw,” a unique structure formed between the human immunodeficiency virus (HIV) that causes AIDS and the cell it infects.

It has been stated, that retroviruses such as HIV establish contact and enter their target cells through the means of an interaction between proteins on the surface of the virus (called spikes) and specific host cell membrane receptors. According to the previous studies, quite a few spikes and some cell receptors are involved in every virus infection event. The findings of the NCI research team has been led by Dr. Sriram Subramaniam, at Laboratory of Cell Biology at NCI’s Center for Cancer Research and has proven the demonstration as true, but in a surprising manner.

It has been reported that a U.S.-Finnish team working in close collaboration with two other groups, has been able to recognize at least four new genetic variants associated with increased risk of diabetes and has also confirmed the existence of another six. It has been affirmed, that the findings of the three groups is to improve at least 10 the number of genetic variants which are self-assuredly associated with increased susceptibility to type 2 diabetes, that affects more than 200 million people worldwide.

Dr. Elias A. Zerhouni, M.D., Director of National Institutes of Health (NIH) said, "This achievement represents a major milestone in our battle against diabetes. It will accelerate efforts to understand the genetic risk factors for this disease, as well as explore how these genetic factors interact with each other and with lifestyle factors. Such research is opening the door to the era of personalized medicine. Our current one-size-fits-all approach will soon give way to more individualized strategies based on each person’s unique genetic make-up."

Advanced Cell Technology, Inc. today here announced of an expanded, non-exclusive commercialization agreement with Wisconsin Alumni Research Foundation (WARF). It has also been avowed, that the expanded agreement grants Advanced Cell rights to the commercial use of human embryonic stem cells (hESCs) for the development of human therapies, with the exception of neuronal, pancreatic beta cells, and cardiac applications, and enables the marketing of a broad collection of research products.

The agreement strengthens Advanced Cell’s existing patent estate at present consists of over 380 owned or licensed patents and patent applications in the international sector. That it has been done through the granting of commercial access to an additional 150 important stem cell technology patents and patent applications, has also come to knowledge.